MP3-14 CHANGES OF THE URINARY NERVE GROWTH FACTOR (NGF) LEVELS AFTER RELIEF OF OBSTRUCTION IN THE PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC OBSTRUCTION (BPO) USING HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP)

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I1 Apr 2015MP3-14 CHANGES OF THE URINARY NERVE GROWTH FACTOR (NGF) LEVELS AFTER RELIEF OF OBSTRUCTION IN THE PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC OBSTRUCTION (BPO) USING HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) Jeongyun Jeong, Tae Heon Kim, Hyun Hwan Sung, Myung-Soo Choo, and Kyu-Sung Lee Jeongyun JeongJeongyun Jeong More articles by this author , Tae Heon KimTae Heon Kim More articles by this author , Hyun Hwan SungHyun Hwan Sung More articles by this author , Myung-Soo ChooMyung-Soo Choo More articles by this author , and Kyu-Sung LeeKyu-Sung Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.117AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urinary NGF levels are increased in the patients with overactive bladder (OAB) and bladder outlet obstruction (BOO). However, the changes of the urinary NGF levels after relief of BOO have been rarely reported. We investigated the changes of urinary NGF levels following HoLEP procedures in the patients with symptomatic BPO. METHODS We measured urinary NGF levels from the voided urine samples of the patients preoperatively, and rechecked urinary NGF levels at 6-month follow-up period postoperatively. We analyzed the clinical features of the 97 patients with more than 6-mo follow-up data using the prospectively collected database. All patients were evaluated with International Prostate Symptom Score (IPSS), International Continence Society male questionnaire short form (ICS-SF), 3-day voiding diary, transrectal ultrasonography, and uroflowmetry with postvoid residual. Urinary NGF level was measured using the enzyme-linked immunosorbent assay (ELISA), and total urinary NGF levels were further normalized to the concentration of urinary creatinine. RESULTS Preoperatively, the urinary NGF and NGF/Cr levels were measured as 93.6±116.3pg/ml and 1.28±1.95, respectively. Patients with more severe storage symptoms showed higher NGF and NGF/Cr levels at the baseline period. However, there was no correlation between these levels and the urodynamic parameters including BOO index (BOOI), bladder contractility index (BCI), maximum cystometric capacity (MCC), and detrusor overactivity (DO). The mean volume of the prostate was 71.9±41.0cc and the mean resected weight was 28.9±27.0g. A significant improvement was achieved in the parameters of IPSS and uroflowmetry at the 6-mo follow-up compared to baseline. Urinary NGF and NGF/Cr levels were decreased significantly at the 6-mo follow-up period from the baseline. However, there was no correlation between the improvement of clinical parameters and the reduction of the NGF and NGF/Cr levels. The changes of the urinary NGF and NGF/Cr levels were not affected by the preoperative urodynamic parameters including BOOI, BCI, MCC, and DO. CONCLUSIONS In the present study, the urinary NGF and NGF/Cr levels were elevated in the patients with BPO, and decreased significantly after successful relief of obstruction using HoLEP. Table. Surgical outcomes after HoLEP procedures including changes of the urinary NGF levels Baseline (n=97) Postop. 6 mo. (n=97) P value NGF (pg/ml) 93.6±116.3 37.2±53.2 <0.001 NGF/Cr 1.28±1.95 0.76±1.41 0.007 IPSS total 22.4± 6.7 7.7±6.0 <0.001 Voiding symptoms 13.2±4.9 2.9±3.8 <0.001 Storage symptoms 9.1±3.1 4.7±3.0 <0.001 QoL index 4.6±3.2 1.9±1.4 <0.001 Voided volume (ml) 175.9±83.7 201.3±117.9 0.132 Qmax (ml/sec) 8.9±9.0 21.4±16.3 0.003 PVR (ml) 110.0±117.5 26.5±22.9 <0.001 PSA level (ng/ml) 4.81±6.17 1.16±2.46 <0.001 HoLEP: holmium laser enucleation of the prostate, NGF: nerve growth factor, IPSS: International Prostate Symptom Score, QoL: quality of life, Qmax: maximal urine flow rate, PVR: post-void residual urine, PSA: prostate specific antigen © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e24 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jeongyun Jeong More articles by this author Tae Heon Kim More articles by this author Hyun Hwan Sung More articles by this author Myung-Soo Choo More articles by this author Kyu-Sung Lee More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...